GOPIVEO Trademark

Trademark Overview

On Wednesday, December 1, 2021, a trademark application was filed for GOPIVEO with the United States Patent and Trademark Office. The USPTO has given the GOPIVEO trademark a serial number of 97150926. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Friday, July 18, 2025. This trademark is owned by Antibe Therapeutics Inc.. The GOPIVEO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals, namely, anti-inflammatories; anti-inflammatory pharmaceutical preparations; preparations for the relief of pain; pharmaceutical preparations for the relief of pain
gopiveo

General Information

Serial Number97150926
Word MarkGOPIVEO
Filing DateWednesday, December 1, 2021
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateFriday, July 18, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceuticals, namely, anti-inflammatories; anti-inflammatory pharmaceutical preparations; preparations for the relief of pain; pharmaceutical preparations for the relief of pain

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, December 6, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAntibe Therapeutics Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressToronto, Ontario M5R1B2
CA

Trademark Events

Event DateEvent Description
Thursday, September 15, 2022SUSPENSION LETTER WRITTEN
Saturday, December 4, 2021NEW APPLICATION ENTERED
Monday, December 6, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, September 10, 2022ASSIGNED TO EXAMINER
Thursday, September 15, 2022LETTER OF SUSPENSION E-MAILED
Thursday, September 15, 2022NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, April 5, 2023SUSPENSION INQUIRY WRITTEN
Wednesday, April 5, 2023INQUIRY TO SUSPENSION E-MAILED
Wednesday, April 5, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Thursday, April 6, 2023SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Monday, April 24, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Thursday, September 7, 2023ASSIGNED TO LIE
Thursday, September 7, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 7, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 8, 2023SUSPENSION LETTER WRITTEN
Friday, September 8, 2023LETTER OF SUSPENSION E-MAILED
Friday, September 8, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, March 18, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Friday, March 28, 2025SUSPENSION INQUIRY WRITTEN
Friday, March 28, 2025INQUIRY TO SUSPENSION E-MAILED
Friday, March 8, 2024SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sunday, September 15, 2024REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Monday, June 30, 2025TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Monday, June 30, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 17, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 17, 2025NON-FINAL ACTION WRITTEN
Thursday, July 17, 2025NON-FINAL ACTION E-MAILED
Friday, July 18, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, July 18, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, July 18, 2025TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 30, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 28, 2025NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

Related Keywords

gopiveo preparations relief anti pain pharmaceutical inflammatory namely inflammatories pharmaceuticals